Articles On Recce Pharmaceuticals (ASX:RCE)

21 Jun 2022 - A snapshot of the stocks on the move, featuring ResApp (ASX:RAP), Radiopharm Theranostics (ASX:RAD), and Reece Pharmaceuticals (ASX:RCE).

ResApp’s independent study of cough app falls short Recce Pharma completes Cohort 6 dosage in Phase 1 trial Proteomics secures exclusive biomakers license Smartphone-based respiratory diagnostic maker, ResApp Health (ASX:RAP), plunged by...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

Recce Pharmaceuticals (RCE) sees its clinical trial receive a good safety profile among ten healthy male subjects The company reported its drug, R327, demonstrated a good tolerability profile among ten male subjects who were intravenously...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Recce Pharmaceuticals (RCE) is set to administer its “high dose” cohort following its successful phase one clinical trial of R327 in the “low dose” cohort The 10 healthy human subjects administered with R327 in the “low dose” cohort showed...

Chimeric wants to accelerate its clinical trial readiness via a deal with WuXi Recce advances to higher dosing in Phase I clinical trial Proteomics engages experts to advance commercialisation Chimeric signs deal with WuXi Cell therapy sp...

Australia-based drug developer Recce Pharmaceuticals (RCE) granted a patent in Hong Kong for two of its synthetic polymer anti-infective drug candidates The patent is called the “Anti-Virus Agent and Method for Treatment of Viral Infection...

ResApp gets takeover offer from Pfizer Recce gets Hong Kong patent RhinoMed comes out of trading halt and rallied 20% Smartphone-based health company ResApp Health (ASX:RAP) surprised the market this morning after revealing that global gi...

Recce Pharmaceuticals (RCE) reports positive safety results from the fourth patient cohort in a first-phase trial of its RECCE 327 (R327) synthetic anti-infective The drug developer dosed 10 healthy male subjects with 1000mg of R327 as par...

Highlights Recce Pharmaceuticals’ R327 exhibits a safe and tolerable profile. The safety profile of R327 at a twenty-fold increase of the initial dosing level is crucial for synergies across the company’s wider-infectious disease portf...

The Tempest, a tale of love, revenge and family set at sea, is thought to be the last play that William Shakespeare wrote alone. One area it doesn’t touch on in detail is staggering riches; a theme now more relevant to shareholders in Tempe...

Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.

ASX-listed Recce Pharmaceuticals (RCE) has developed a synthetic anti-infective designed to not only kill bacteria and emerging viral pathogens but treat sepsis before it can take hold Sepsis is the leading cause of hospitalisation in the...

Recce Pharmaceuticals’ (RCE) new class of synthetic anti-infectives drug, the RECCE 327 (R327) has been given the go-ahead for the next set of doses by an Independent Safety Committee (ISC) following a successful Phase I intravenous (IV) c...

Highlights The ASX 200 was trading 0.31% up at 7,113.8 in the first 15 minutes of trading. Brent crude oil rallied sharply to over US$139 per barrel mark on Monday. The energy index was the top gainer, surging 4.69% in early trade....

The ASX 200 Health Index (XHJ) is trading lower by 1.40% at the time of writing, compared to the broader index which is down by 0.35%. Cell therapy specialist Chimeric Therapeutics (ASX:CHM) has just announced the final results of its Phase...

Recce Pharmaceuticals (RCE) doses the final three patients under cohort three of the Phase I intravenous (IV) clinical trial of RECCE327 (R327) The study is evaluating the safety and pharmacokinetics of R327 in seven to 10 subjects with do...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.90%, while the benchmark ASX 200 has fallen by 0.3%. Genomics specialist Genetic Technologies (ASX:GTG) says that its laboratory in Fitzroy, Melbourne has received simultan...

“Completing this Cohort with the maximum number of subjects, sees R327 (500mg, I.V.) further a compelling Safety profile at a milestone dose. We anticipate recommendation to start dosing Cohort 4 at higher concentrations again in near weeks...

Recce Pharmaceuticals’ (RCE) phase-one intravenous clinical of R327 indicates a good safety and tolerability profile among seven healthy male subjects The company says its cohort three was tested with 500 mg of R327, which is designed for...

NeuroScientific Biopharmaceuticals (ASX:NSB) share price jumped ~13% today to 35 cents after an update on its lead drug candidate EmtinB. The company said it has executed on the successful completion of invitro genotoxicity and plasma prote...

According to PEW Charitable Trusts global antibiotic pipeline review, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

Recce Pharmaceuticals (RCE) ended the December quarter with a cash balance of $15.83 million post research and development (R&D) costs of $1.54 million During the quarter, Recce reported positive data from its phase 1 and 2 clinical t...

The ASX 200 posted a small 0.11 fall on Tuesday, outperformed by the small end of town as the microcap Emerging Companies index rose by 0.66%. There were no clear catalysts as Asian markets struggled for direction after Wall Street was clos...

Recce Pharmaceuticals (RCE) has released positive safety data from its second cohort of subjects for its Phase I intravenous clinical trial of RECCE 327 (R327) R327 is designed to treat serious bacterial infections including sepsis. The se...

Key Points The Recce share price is up 3.85% to $1.35 An independent safety committee has cleared stronger dosing of Recce 327 Trial subjects are expected to be recruited sometime this week The Recce Pharmaceuticals Ltd (ASX: RCE) share...

According to PEW Charitable Trusts global antibiotic pipeline review, RECCE 327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

The ASX has recovered following yesterday’s strong blow, closing up 1.29% with all 11 sectors finishing in the green on lower than normal trading volumes. Today’s biggest sector win was energy, up a nice 2.20% with the financial market foll...

Recce Pharmaceuticals (RCE) announces positive data from its phase one intravenous clinical trial for RECCE 327 (R327) R327 is designed to treat serious bacterial infections including sepsis In its first cohort of the phase one trial, nine...

According to PEW Charitable Trust, R327 is the only clinical-stage new class of antibiotic in the world being developed for sepsis, the largest unmet medical need in human health.

Synthetic anti-infectives company Recce Pharmaceuticals (ASX:RCE) has announced it has recruited the first cohort of 10 healthy male subjects in its Phase I intravenous clinical trial of its lead compound.

R327 is administered as a single dose via a 1-hour IV infusion at a uniform rate, with all 80 subjects anticipated to have been dosed by the end of H1 2022.

Synthetic anti-infective company Recce Pharmaceuticals (ASX:RCE) has provided an update on its Phase I/II clinical trial for the treatment of burn wound infections.

Recce Pharmaceuticals’ share price has been boosted this morning on positive news about one of its drugs working on Perth patients with infected burns wounds.

“This initial update builds upon strong pre-clinical data demonstrating fast and efficient killing activity against common and problematic bacterial strains, and we are excited for the potential of R327 in the clinic," says CEO.

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

Recce Pharmaceuticals (RCE) provides an update in the clinical trial of RECCE 327 (R327) for the treatment of burn wound infections RCE reports broad spectrum antibiotic activity on bacterial burn wound infections with a visible infection...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price is soaring today. This comes after the pharmaceutical company provided an update on its clinical trial for the treatment of burn wound infections. At the time of writing, the Recce share...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

In March this year, Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.

Receiving human ethics approval is a momentous achievement for Recce and the clinicians seeking effective treatments to combat antibiotic-resistant bacteria,” says chairman.

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327) The phase one trial is a randomised, placebo-controlled, ascending-dose, single-dose...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is higher by 0.7%. Notices from both the Australian and European Patent Offices have been received by Noxopharm (ASX:NOX), relating to...

The misuse and overuse of antibiotics have led to the rapid growth of superbugs – a type of bacteria resistant to conventional treatments Serious infections such as pneumonia, tuberculosis and salmonella are becoming difficult to treat as...

The ASX retreated again as angst over inflation and the withdrawal of stimulus continued to weigh on global markets. The ASX 200 closed at 7,300 – 0.28% lower than Friday’s close. Tech was the biggest laggard, losing nearly 3% but energy an...

The Recce Pharmaceuticals Ltd (ASX: RCE) share price was halted today after the company made a key announcement. Recce shares were trading 1.61% lower at 91.5 cents before being placed into a trading halt. Let’s get into the thick of it t...

The ASX had a positive end to the week with the ASX 200 gaining 0.87% today taking its weekly gain to 1.9%. All sectors gained with the best being resources which gained nearly 1.7%. Australia’s rise was in line with the broader Asia-Pacifi...

Superbugs that are resistant to antibiotics are causing an urgent global health crisis, but Recce Pharmaceuticals believes it has the solution.